The U.S. healthcare system, including patients, employers and taxpayers, saved $408 billion in 2022 by using FDA-approved generic and biosimilar drugs, per the AAM's report.
The proposed settlement, which needs court approval, will provide consumers who participated in the lawsuit with “approximately double their out-of-pocket damages,” according to reports.
The company said it leverages the clinical expertise of pharmacy teams to conduct custom savings reviews, with each patient’s medical and cost of its history in mind.